Retour sur lavenir.net
   AB INBEV 69.640 € (+1,40 %)     RECTICEL 12.700 € (+1,44 %)     ACKERMANS V.HAAREN 263.400 € (-0,23 %)     NEXTENSA 45.600 € (-1,39 %)     KINEPOLIS GROUP 40.900 € (+0,62 %)     KBC ANCORA 91.900 € (+0,44 %)     WDP 21.300 € (-0,37 %)     GIMV 43.800 € (-0,34 %)     SOLVAY 26.200 € (-1,65 %)     LOTUS BAKERIES 12 680.000 € (+2,76 %)     AEDIFICA 68.000 € (-0,15 %)     SIPEF 99.000 € (+6,80 %)     KBC 130.300 € (+0,50 %)     TITAN S.A. 51.400 € (+0,78 %)     ARGENX SE 754.400 € (-0,87 %)     BREDERODE 102.800 € (-0,19 %)     CARE PROPERTY INV. 12.100 € (-0,49 %)     ONTEX GROUP 2.470 € (-1,00 %)     VAN DE VELDE 29.600 € (-0,34 %)     D'IETEREN GROUP 175.000 € (-0,91 %)     GBL 75.000 € (-0,99 %)     TUBIZE-FIN 183.700 € (-1,66 %)     CFE 11.800 € (-1,67 %)     MELEXIS 71.550 € (-1,31 %)     MATERIALISE 5.800 € (-2,52 %)     SYENSQO 80.200 € (-0,74 %)     DECEUNINCK 2.225 € (+0,23 %)     UMICORE 23.240 € (-4,05 %)     BARCO 7.910 € (-0,50 %)     TINC 11.200 € (-0,18 %)     BELYSSE GROUP 0.473 € (-1,46 %)     NYRSTAR 0.061 € (0,00 %)     ORANGE BELGIUM 22.000 € (0,00 %)     ELIA GROUP 132.000 € (+0,69 %)     BEKAERT 38.100 € (+0,66 %)     ECONOCOM GROUP 1.455 € (-2,35 %)     WERELDHAVE BELGIUM 52.400 € (-0,76 %)     INCLUSIO SA/NV 17.200 € (-1,15 %)     FAGRON 22.300 € (+0,45 %)     HOME INVEST BE. 19.240 € (-0,72 %)     VASTNED 29.050 € (0,00 %)     QUESTFOR GR-PRICAF 3.048 € (+1,60 %)     XIOR 27.250 € (-1,09 %)     UCB 219.100 € (-1,22 %)     JENSEN-GROUP 72.200 € (-0,82 %)     NYXOAH 1.384 € (-1,00 %)     VIOHALCO 17.660 € (-1,89 %)     SOFINA 248.200 € (-0,24 %)     BPOST 1.388 € (-0,72 %)     FLUXYS BELGIUM D 20.400 € (+1,49 %)     CENERGY 22.940 € (+2,78 %)     TESSENDERLO 20.850 € (-2,11 %)     PROXIMUS 6.240 € (-0,40 %)     MONTEA 66.000 € (-1,05 %)     COLRUYT 38.500 € (+0,68 %)     CAMPINE 203.000 € (+0,50 %)     CMB.TECH 14.720 € (+2,22 %)     AGEAS 72.350 € (-0,55 %)     ENERGYVISION 15.220 € (-1,68 %)     EVS 28.350 € (+1,43 %)  
   CVC CAPITAL 15.290 € (+0,46 %)     HAFFNER ENERGY 0.620 € (-10,66 %)     VINCI 121.950 € (-1,09 %)     AHOLD DEL 32.460 € (+1,85 %)     EXAIL TECHNOLOGIES 124.500 € (-0,24 %)     CARREFOUR 15.725 € (-0,19 %)     PROSUS 38.100 € (-1,45 %)     UNILEVER 54.170 € (+0,99 %)     SAFRAN 358.000 € (-1,54 %)     ASML HOLDING 1 609.400 € (+2,71 %)     BANIJAY GROUP 10.100 € (+10,02 %)     BE SEMICONDUCTOR 235.200 € (+1,47 %)     MEDIANTECHNOLOGIES 4.710 € (+1,84 %)     CSG 18.888 € (+2,37 %)     ASM INTERNATIONAL 907.800 € (+1,11 %)     ING GROEP N.V. 30.820 € (-0,26 %)     Vusion 133.300 € (+0,98 %)     ALTHEORA 0.386 € (-5,85 %)     FASTNED 35.800 € (+9,15 %)     AMG 33.660 € (-0,53 %)     COFACE 15.920 € (-0,62 %)     HAL TRUST 165.000 € (0,00 %)     THALES 268.600 € (-1,21 %)     BIOSYNEX 1.000 € (0,00 %)     SCHNEIDER ELECTRIC 309.250 € (-0,56 %)     ADYEN 1 059.200 € (+16,40 %)     ARCELORMITTAL SA 63.660 € (-0,81 %)     NEXANS 142.500 € (-1,52 %)     S.E.B. 59.600 € (+1,62 %)     LVMH 460.000 € (-1,06 %)     TRIODOS BANK 34.700 € (+9,46 %)     SPINEGUARD 0.087 € (-0,57 %)     VOPAK 47.160 € (+0,26 %)     AKWEL 6.700 € (-0,89 %)     SEMCO TECHNOLOGIES 45.000 € (-0,66 %)     SCOR SE 34.080 € (-0,53 %)     EIFFAGE 121.250 € (-0,70 %)     GECINA 74.050 € (-0,07 %)     ABN AMRO BANK N.V. 41.500 € (-0,69 %)     NANOBIOTIX 33.180 € (-3,88 %)     LOUIS HACHETTE 1.870 € (+0,48 %)     SHELL PLC 38.605 € (-0,25 %)     HAVAS 18.700 € (-2,09 %)     CORBION 19.750 € (+0,30 %)     SOCIETE GENERALE 82.870 € (-0,30 %)     MAGNUM 17.340 € (+2,11 %)     BIOPHYTIS 0.057 € (+51,47 %)     AEGON 8.150 € (-0,61 %)     UMG 14.650 € (-1,55 %)     ACCOR 46.560 € (+0,47 %)     PHILIPS KON 23.690 € (+2,16 %)     CRCAM LANGUED CCI 91.000 € (0,00 %)     KAUFMAN ET BROAD 24.950 € (-0,20 %)     HEXAOM 29.000 € (+3,20 %)     CARMILA 16.580 € (-0,60 %)     WOLTERS KLUWER 68.320 € (-1,21 %)     CROSSJECT 1.434 € (-2,32 %)     PHARMING GROUP 1.028 € (+2,39 %)     LAKEFRONT BIOTHER. 24.300 € (-0,57 %)     ALTAREA 98.800 € (-0,30 %)  
News Réglementées
13/08/2026 14:20

Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026

EQS-News: Axtria, Inc. / Key word(s): Private Equity/Expansion
Axtria to Build Industry's Largest Pharma-Specific AI Engineering Team, Scaling to 1,000 by December 2026

13.08.2026 / 14:20 CET/CEST
The issuer is solely responsible for the content of this announcement.


NEW DELHI, Aug. 13, 2026 /PRNewswire/ -- Axtria Inc.,  a global leader in AI-first data analytics solutions for the life sciences industry, today announced plans to expand its Forward Deployed Engineering (FDE) organization to 1,000 engineers by December 2026, creating the industry's largest pharma-specific AI engineering team. The expansion represents one of Axtria's largest investments in AI talent development to date and reflects growing customer demand for engineers who can deploy, scale, and operationalize enterprise AI across commercial, medical, and market access functions.

Axtria Logo

Launched approximately 12 months ago, Axtria's Forward Deployed Engineering model was built on a simple premise: the future of AI in life sciences will be determined not by who has access to the best models, but by who can successfully deploy AI into complex enterprise environments and deliver measurable business outcomes. Today, Axtria's FDEs are embedded within leading life sciences organizations, deploying production-grade AI solutions across commercial and medical operations. Building on this momentum, Axtria is expanding the organization to 1,000 engineers by December 2026 through a combination of internal talent development and strategic hiring.

While life sciences organizations have invested heavily in modern data platforms and generative AI, many continue to face a shortage of specialized talent capable of deploying AI at enterprise scale. Technology providers often bring strong AI engineering capabilities but lack deep life sciences expertise, while in-house pharma teams understand the business but cannot always keep pace with the rapidly evolving AI ecosystem. Axtria's Forward Deployed Engineering model bridges this gap by combining both disciplines into a single engineering organization that helps clients move from AI experimentation to enterprise-scale deployment.

Axtria's Forward Deployed Engineers are trained and certified across leading AI and cloud platforms, including Anthropic, AWS, Databricks, LangChain, Microsoft, and Snowflake. Through the Axtria Institute, the company is developing life sciences domain experts into certified AI engineers who deploy solutions across Industry leading platforms and Axtria's proprietary platforms—including SalesIQ™, MarketingIQ™ and  DataMAx™, helping clients modernize data foundations, improve decision-making, and scale enterprise AI with strong governance and cost efficiency.

"The industry is moving beyond AI experimentation to enterprise-wide deployment, and success now depends on execution," said Navi Chadha, CTO and Co-founder, Axtria. "Our Forward Deployed Engineers combine deep life sciences expertise with world-class AI engineering capabilities to help clients operationalize AI at scale. This expansion reflects both the demand we're seeing from customers and our commitment to building the talent needed to power the next generation of AI-enabled life sciences organizations."

"The most important investment we're making is in people," said Manish Mittal, Managing Principal and Country Head, Axtria. "Through the Axtria Institute, we're enabling our own life sciences experts to become certified AI engineers while also attracting exceptional engineering talent from the market. This creates unique career opportunities and ensures our clients have access to specialists who understand both the science of AI and the realities of life sciences.

Learn more about Axtria's Forward Deployed Engineering model or explore FDE careers.

About Axtria 

Axtria helps life sciences companies harness the potential of data science and software to improve patient outcomes by connecting the right therapies to the right patients at the right time. A leading global provider of award-winning cloud software and data analytics, Axtria delivers proven solutions that help pharmaceutical, medical device, and diagnostics companies complete their journey from data to insights to action. As a participant in the United Nations Global Compact, Axtria is committed to aligning strategies and operations with universal principles on human rights, labor, environment, and anti-corruption. For more information, visit www.axtria.com

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/axtria-to-build-industrys-largest-pharma-specific-ai-engineering-team-scaling-to-1-000-by-december-2026--302850759.html

rt.gif?NewsItemId=EN25810&Transmission_Id=202608130815PR_NEWS_EURO_ND__EN25810&DateId=20260813


13.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2382640  13.08.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière